The treatment outcome of T2 laryngeal squamous cell carcinoma in one institution with long term follow-up: Radiotherapy alone vs Chemoradiotherapy

Korean Journal of Head & Neck Oncology 2018;34(2):11-15.
Published online November 30, 2018.

Seong-Min Jin;Jae-Gu Kim;Kyeong-Suk Park;Ik-Joo Chung;Woong-Ki Chung;Dong-Hoon Lee;Joon-Kyoo Lee;Sang-Chul Lim;Tae-Mi Yoon

T2 후두 편평세포암종에서 단독 방사선치료와 항암방사선병합치료의 비교 연구

진성민;김재구;박경석;정익주;정웅기;이동훈;이준규;임상철;윤태미

Abstract

Background/Objectives
The efficacy of radiotherapy alone versus chemoradiotherapy has been studied in patients with T2N0M0 laryngeal squamous cell carcinoma.
Materials & Methods
Thirty nine patients with newly diagnosed T2N0M0 laryngeal squamous cell carcinoma were treated with either radiotherapy(RT group, 66-70Gy) or chemoradiotherapy(CRT group, cisplatin based concurrent chemoradiation with or without 2 cycles induction chemotherapy including cisplatin, 5-FU± docetaxel / radiation therapy same with above mentioned). The mean follow-up was 73.5 months.
Results
The overall survival (OS), disease specific survival (DSS), disease free survival (DFS), and larynx preservation survival (LPS) at 5 years were 70%, 79%, 67%, and 71%. The complete response rate was 82.4% in RT group, and was 95.5% in CRT group. OS (57% vs 80%), DSS (69% vs 86%), DFS (52% vs 77%), and LPS (63% vs 77%) at 5 years were higher in CRT group than RT group, but it was not statistically significant. In subsite analysis, CRT group tends to improve DFS, compared to RT group, in glottic cancer (p=0.06). The toxicities were tolerable and no fatal case was observed in both groups.
Conclusion
Chemoradiotherapy is effective as primary therapy for T2 laryngeal squamous cell carcinoma and showed manageable treatment induced toxicity.

Key Words: Head and neck neoplasms, Radiotherapy, Chemotherapy